PLx Pharma Inc. (PLXP) |
| 0.087 0 (0%) 04-12 16:00 |
| Open: | 0.0953 |
| High: | 0.1555 |
| Low: | 0.0826 |
| Volume: | 50,382,179 |
| Market Cap: | 3(M) |
| PE Ratio: | -0.22 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 3.41 |
| 52w Low: | 0.009 |
PLx Pharma Inc. is a U.S.-based entity leveraging its innovative drug delivery platform technology, having successfully transitioned into the commercial stage. The company's primary offerings include Vazalore 325 mg, which is formulated for individuals facing vascular incidents like heart attacks and clot-induced strokes, as well as for the management of pain and inflammation. Additionally, they provide Vazalore 81 mg in the form of liquid-filled aspirin capsules. Looking ahead, their product development pipeline features PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, both of which are in Phase I clinical trials for addressing pain, inflammation, and fever. PLx Pharma makes its products available to consumers through a variety of retail avenues, including pharmacies, major retailers, supermarkets, and online sales channels. Founded in 2002, PLx Pharma Inc. is headquartered in Sparta, New Jersey.
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Wed, 12 Apr 2023
PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets - Yahoo Finance
Thu, 16 Jun 2022
PLx Pharma Inc. (PLXP) Share Price Today | PLx Pharma (PLXP) Live NSE/BSE - Value Research
Mon, 20 Sep 2021
A New Aspirin From PLX Has Investors’ Hearts Pounding - Barron's
Thu, 26 Aug 2021
PLx Pharma Inc.’s VAZALORE™ Now on Shelves; National Media Campaign Launches Today - Yahoo Finance
Mon, 01 Mar 2021
PLx Pharma Receives FDA Approval of SNDAs for Both VAZALORE 325 mg and 81 mg - GlobeNewswire
Mon, 27 Jul 2026
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |